RxDoctor Payments DataLook up a doctor →

Steven Stroud, MD

Advanced Heart Failure and Transplant Cardiology · Tulsa, OKNPI 1730567124

Payments from drug & device makers

$1,129,955in general payments, 2019–2025

Across 441 payments — averaging $2562.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1M
  • United Therapeutics Corporation$114K
  • Actelion Pharmaceuticals US, Inc.$7K
  • Abiomed$2K
  • Abbott$2K
  • Merck$793
  • plus $4K from 24 others

What the payments were for

  • Consulting fees$20,71053%
  • Travel & lodging$4,61212%
  • Food & beverage$13,76435%
  • Education$1270%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$82,722
Medicare patients
257
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag71$1,679,285
Tyvaso DpiTreprostinil57$1,311,670
WinrevairSotatercept-Csrk29$409,248
CamzyosMavacamten37$304,019
OpsumitMacitentan23$291,054
Orenitram ErTreprostinil Diolamine35$249,649
JardianceEmpagliflozin202$155,205
AdempasRiociguat11$152,037
Ambrisentan31$141,436
EntrestoSacubitril/Valsartan131$113,616
FarxigaDapagliflozin Propanediol105$75,695
EliquisApixaban86$66,592
Tadalafil81$48,601
WegovySemaglutide20$26,509
Sildenafil Citrate30$9,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$7,088$1,970,33994 claims
MerckWinrevair$793$409,24829 claims
E.r. Squibb & Sons, L.L.C.Camzyos$473$304,01937 claims
Boehringer IngelheimJardiance$136$155,205202 claims
BayerAdempas$351$152,03711 claims
NovartisEntresto$47$113,616131 claims
AstraZenecaFarxiga$491$75,695105 claims
PfizerEliquis$249$66,59286 claims
Novo NordiskWegovy$39$26,50920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →